UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.

被引：0
|
作者：
Gaut, Daria Louise
Callas, Bradley
Damon, Lloyd Earl
Jonas, Brian Andrew
Jeyakumar, Deepa
Borror, Catherine
Osorio, Stephanie
Ta, Teresa
Park, Sunmin
Schiller, Gary J.
Wieduwilt, Matthew Joseph
Oliai, Caspian
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Calif San Francisco, San Francisco, CA USA
[3] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
[4] Univ Calif Irvine, Irvine, CA USA
[5] Univ Calif Davis, Sacramento, CA USA
[6] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[7] David Geffen Sch Med UCLA, Los Angeles, CA USA
[8] Wake Forest Univ, Winston Salem, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7024
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial
    Oliai, Caspian
    Park, Sunmin
    Damon, Lloyd E.
    Jonas, Brian A.
    Jeyakumar, Deepa
    Wieduwilt, Matthew J.
    Logan, Aaron C.
    Callas, Bradley
    Hannigan, Chris A.
    Gaut, Daria L.
    Schiller, Gary J.
    LEUKEMIA & LYMPHOMA, 2024,
  • [2] Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
    Chan, Onyee
    Sweet, Kendra L.
    Talati, Chetasi
    Zahra, Fatima Tuz
    Nardelli, Lisa Ann
    Lamba, Jatinder K.
    Kim, Jongphil
    Song, Jinming
    Xie, Zhuoer
    Yun, Seongseok
    Kuykendall, Andrew T.
    Padron, Eric
    Walker, Alison R.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Sallman, David
    BLOOD, 2024, 144 : 4270 - 4271
  • [3] Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Przespolewski, Amanda
    Griffiths, Elizabeth A.
    Thompson, James E.
    Elshoury, Amro
    Emadi, Ashkan
    Duong, Vu H.
    Niyongere, Sandrine
    Walinski, Wendy
    Said, Meriem
    Halliwell, Stephanie
    Eke, Kemji
    Attwood, Kristopher
    Baer, Maria R.
    Wang, Eunice S.
    BLOOD, 2020, 136
  • [4] Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Bharathi, Vanthana
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Jabbour, Elias
    Daver, Naval
    Short, Nicholas J.
    Takahashi, Koichi
    Issa, Ghayas C.
    Dinardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2024, 144 : 4272 - 4274
  • [5] Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+Relapsed or Refractory Acute Myeloid Leukemia
    Swaminathan, Mahesh
    Przespolewski, Amanda
    Griffiths, Elizabeth A.
    Thompson, James E.
    Elshoury, Amro
    Walinski, Wendy
    Said, Meriem
    Halliwell, Stephanie
    Puff, Claire
    Attwood, Kristopher
    Wang, Eunice S.
    BLOOD, 2021, 138
  • [6] CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Short, Nicholas J.
    Jabbour, Elias
    Takahashi, Koichi
    Daver, Naval
    Issa, Ghayas C.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [7] V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.
    Agresta, Laura
    O'Brien, Maureen Megan
    O'Brien, Eric Justin
    Norris, Robin Elizabeth
    Breese, Erin Haag
    Burns, Karen Cristly
    Mizukawa, Benjamin
    Ryan, Thomas D.
    Desai, Pankaj B.
    Vinks, A. A.
    Grimes, H. Leighton
    Absalon, Michael
    Perentesis, John Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas
    Piccaluga, PP
    Martinelli, G
    Rondoni, M
    Malagola, M
    Gaitani, S
    Isidori, A
    Bonini, A
    Gugliotta, L
    Luppi, M
    Morselli, M
    Sparaventi, G
    Visani, G
    Baccarani, M
    LEUKEMIA & LYMPHOMA, 2004, 45 (09) : 1791 - 1795
  • [9] Gemtuzumab ozogamicin with FLAG-IDA is effective for children in relapsed/refractory acute myeloid leukemia.
    Cho, Bin
    Kim, Sun Young
    Lee, Dae Hyoung
    Kwon, Young Joo
    Park, Young Shil
    Hwang, Hui Sung
    Park, Ji Kyoung
    Jang, Pil Sang
    Chung, Nak Gyun
    Jeong, Dae-Chul
    Kim, Hack Ki
    BLOOD, 2006, 108 (11) : 218B - 218B
  • [10] A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kim, Kunhwa
    Kantarjian, Hagop
    Borthakur, Gautam
    Takahashi, Koichi
    Short, Nicholas J.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Chien, Kelly S.
    Daver, Naval
    Pemmaraju, Naveen
    Jain, Nitin
    Adewale, Lade
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Verstovsek, Srdan
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
12345